nucleolar protein 4Genealiases: CT125 · HRIHFB2255 · NOLP
Q-omics provides the consensus-scored NOL4 profile across patient tissues and cancer cell-line models. NOL4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NOL4 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, NOL4 RNA expression shows 14,577 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight MESO, THCA, and PCPG as cancer lineages where NOL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOL4 survival associations across molecular data types. NOL4 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOL4 RNA expression–survival associations across cancer types. High NOL4 expression shows unfavorable associations in MESO, UCEC and HNSC, but favorable associations in LGG, PAAD and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NOL4 RNA expression.
This table summarizes NOL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NOL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOL4 shows lower tumor expression in THCA, KICH, COAD, BLCA, LIHC and READ. The THCA box plot shows higher NOL4 RNA expression in normal versus tumor tissue (log2 FC = −2.378, t-test p < 0.001).
This table shows molecular features associated with NOL4 in patient tissues and cancer cell lines. In patient samples, NOL4 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, NOL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
